Medtronic Care - HF

 

Medtronic

Indications, contraindications, warnings, precautions, and adverse events

Privacy Statement
Terms of Use

Study Design

CareHF Study design

*Patients with QRS 120-149 ms were required to meet echocardiographic evidence for ventricular dyssynchrony including aortic pre-ejection delay 140ms, interventricular mechanical delay 40ms and  delayed activation of posterolateral LV-wall.

CARE-HF was a multicenter, international, randomized trial. 813 patients were enrolled in 82 European centers and followed for a minimum of 18 months (mean 29.4 months, range 18.0 to 44.7 months). Patients with left ventricular systolic dysfunction, cardiac dyssynchrony, and symptomatic heart failure were randomized as follows:

  • 404 patient - Optimal medical therapy (OMT) alone
  • 409 patients - Optimal medical therapy + Medtronic CRT
Patients were evaluated at three-month intervals for 18 months, and every six months thereafter until the end of the study. Follow-up continued for 18 months after the enrollment of the last patient .